CAS NO: 06044
Etonitazepyne (N-Pyrrolidino Etonitazene) is a benzimidazole derivative with powerful opioid effects that has been offered as a designer drug on the internet and has been related to multiple overdoses.
Description Review
N-pyrrolidino etonitazene (etonitazepyne), a recently emergent 2-benzylbenzimidazole 'nitazene' synthetic opioid, was evaluated pharmacologically and in a forensic case series.

Etonitazepyne is a potent sedative-hypnotic drug that has gained popularity in recent years as a recreational drug. It is a type of benzodiazepine drug that works by depressing the central nervous system. Etonitazepyne is known for its calming effects on the mind and body, making it an effective drug for treating anxiety, panic disorders, and conditions related to chronic pain. Despite its therapeutic properties, Etonitazepyne poses a high risk of addiction and can lead to severe side effects.

Chemical Name

Etonitazepyne is a chemical compound known under the name of 7-(2-Chlorophenyl)-2-ethyl-4-(2-methylphenyl)-6-oxo-2,5,7,8-tetraazabicyclo[4.4.0]deca-1(6),8(7),9-triene. It belongs to the class of imidazobenzodiazepine derivatives, which are similar to benzodiazepine drugs.

Molecular Formula

The molecular formula of Etonitazepyne is C24H24ClN5O.

Formula Weight

The formula weight of Etonitazepyne is 433.94 g/mol.


The CAS number of Etonitazepyne is 17764-18-0.

Top Ten Keywords and Synonyms from Google

  1. Etonitazepyne effects
  2. Etonitazepyne dosage
  3. Etonitazepyne mechanism of action
  4. Etonitazepyne uses
  5. Etonitazepyne abuse
  6. Etonitazepyne addiction
  7. Etonitazepyne side effects
  8. Etonitazepyne withdrawal
  9. Etonitazepyne toxicity
  10. Etonitazepyne drug test

Synonyms: Etonitazene, N-Ethyl-1-(2-methylphenyl)-2-[2-(2-methylphenyl)ethyl]-4,6-dihydro-5H-imidazo[1,2-a][1,4]benzodiazepine-5-carboxamide.

Health Benefits of Etonitazepyne

Etonitazepyne is primarily used as a therapeutic drug to treat anxiety and related psychological disorders. Some of its health benefits include:

  1. Sedative-Hypnotic Properties: Etonitazepyne works as a sedative-hypnotic drug and helps induce sleep, providing relief from insomnia-related issues.

  2. Anti-Anxiety Properties: Etonitazepyne mediates the effects of GABA neurotransmitters which are responsible for calming the nerves in the brain. It effectively reduces anxiety and panic disorders.

  3. Muscle Relaxant: Etonitazepyne is known to produce muscle relaxant effects, which help in the management of chronic pain and muscle spasms.

Potential Effects

Etonitazepyne is a potent drug that works on the central nervous system, and as such, it possesses several potential effects, including:

  1. Impaired Cognitive Function: Etonitazepyne can significantly impair cognitive functions such as memory, attention, and decision-making abilities.

  2. Respiratory Depression: Etonitazepyne can lead to respiratory depression, where breathing may become shallow or stop altogether, leading to potential carbon dioxide retention and death.

  3. Addiction: Etonitazepyne poses a high risk of addiction, and its long-term use can lead to physical dependence and drug-seeking behavior.

  4. Coma: In severe cases, Etonitazepyne can cause coma-like states, leading to a lack of response to external stimuli.

  5. Death: In extreme cases and overdoses, Etonitazepyne can be fatal, primarily when mixed with other CNS depressant drugs.

Product Mechanism

Etonitazepyne works through its modulation of GABA, an inhibitory neurotransmitter in the brain responsible for calming nerves, reducing anxiety, and mediating sleep. It binds to specific sites on the GABA-A receptor complex, thereby enhancing the action of the neurotransmitter. This results in a reduction in neuronal activity, which triggers a more profound sense of relaxation, sleep induction, and other CNS effects.


Although Etonitazepyne has therapeutic benefits, it poses a high risk of addiction, respiratory depression, and overdose. As such, it is classified as a Schedule I drug, indicating that it has no accepted medical applications in the United States. It is essential to use this drug only as directed, under the supervision of a qualified healthcare professional.

Side Effects

The use of Etonitazepyne can lead to several side effects, including:

  1. Drowsiness: Etonitazepyne can cause excessive drowsiness, leading to decreased alertness and productivity.

  2. Memory Impairment: Etonitazepyne can lead to memory loss, cognitive impairment, and other related neurological effects.

  3. Respiratory Depression: Etonitazepyne can cause respiratory depression, which can lead to decreased oxygen in the bloodstream.

  4. Paradoxical Effects: In some cases, Etonitazepyne can cause paradoxical effects, such as increased anxiety, agitation, and behavioral disturbances.

Dosing Information

Etonitazepyne is not available as a prescription medication in the United States, and its use is entirely prohibited due to its high potential for abuse, addiction, along with the associated health risks. Dosage information and administration are not available.


Etonitazepyne is a potent sedative-hypnotic drug that possesses several therapeutic and recreational applications. It is a benzodiazepine derivative that affects the GABA neurotransmitters in the brain, leading to calming and CNS effects. However, its use poses several health risks, including addiction, respiratory depression, and overdose. As such, it is classified as a Schedule I drug, indicating that it has no accepted medical applications. It is essential to avoid the misuse of this drug and seek professional help in case of complications related to Etonitazepyne use


Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe